A cracker of a year Yesterday (25 th August) I made my way down to Melbourne for a presentation by Cellestis at [Read More...]undefinedShaw Stockbroking. The presentation was preceded by publication of the Preliminary Results for 2009. These preliminary results are most satisfying, the Company has achieved a doubling of unit sales for the financial year accompanied by a per unit reduction of costs resulting in a healthy profit. The presentation was equally impressive - the Company's aim is to maintain this growth with QFT becoming the dominant diagnostic in the latent TB market and there is no reason why this will not happen.
During a previous presentation Tony Radford discussed the concept of "tipping points". This now seems irrelevant - QFT has achieved universal acceptance as the superior diagnostic for latent TB. The job ahead is to sell the implementation of QFT.
What struck me was that the Company has no real need to make broker presentations. Patience, persistence and hard work has paid off for the two intelligent and thrifty principals, Drs Tony Radford and Jim Rothel. In 9 years the Company has grown from what could have just been "another good idea" to a Company that has achieved the global recognition and approval of its peers. By being consistently good managers they are achieving their goals without the burden of debt and with the solid support of shareholders and these presentations are more a means of communicating with shareholders rather than stock brokers.
On a personal level I find that I always learn something new and yesterday Tony Radford raised the important point that its not just a simple matter of marketplace buyers and sellers of products or services it is one of partners, including shareholders.
So it is a big thank you from me (and I am sure from many others) to Tony Radford and Jim Rothel for taking the time and going to the trouble of keeping me so well informed.
CST Price at posting:
$3.50 Sentiment: Hold Disclosure: Held
